Looking Into AbbVie's Return On Capital Employed
Looking at Q3, AbbVie (NYSE: ABBV) earned $3.25 billion, a 332.85% increase from the preceding quarter. AbbVie also posted a total of $12.90 billion in sales, a 23.76% increase since Q2. AbbVie earned $752.00 million, and sales totaled $10.43 billion in Q2.
What Is ROCE?
Changes in earnings and sales indicate shifts in AbbVie’s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, AbbVie posted an ROCE of 0.21%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.
For AbbVie, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.
Q3 Earnings Recap
AbbVie reported Q3 earnings per share at $2.83/share, which beat analyst predictions of $2.76/share.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
